incadronic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| calcium metabolism regulator, pharmaceutical aid | 1431 | 124351-85-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
increases serum 1,25-dihydroxyvitamin D in rats via stimulating renal 1-hydroxylase activity; structure given in first source
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 1 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.24 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.16 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.90 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.82 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1997 | PMDA | Astellas |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D050071 | Bone Density Conservation Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Humoral hypercalcemia of malignancy | indication | 47709007 | |
| Osteoporosis | indication | 64859006 | DOID:11476 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.95 | acidic |
| pKa2 | 4.93 | acidic |
| pKa3 | 9.0 | acidic |
| pKa4 | 12.0 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Farnesyl pyrophosphate synthase | Enzyme | INHIBITOR | IC50 | 7.52 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| Farnesyl pyrophosphate synthase | Enzyme | IC50 | 6.80 | CHEMBL | |||||
| Vacuolar-type proton translocating pyrophosphatase 1 | Unclassified | IC50 | 4.35 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D08073 | KEGG_DRUG |
| C1881172 | UMLSCUI |
| CHEBI:135189 | CHEBI |
| CHEMBL53950 | ChEMBL_ID |
| DB06255 | DRUGBANK_ID |
| C071542 | MESH_SUPPLEMENTAL_RECORD_UI |
| 3699 | PUBCHEM_CID |
| 3174 | IUPHAR_LIGAND_ID |
| 7122 | INN_ID |
| 138330-18-4 | SECONDARY_CAS_RN |
| G5C4M8847E | UNII |
| CHEMBL56253 | ChEMBL_ID |
Pharmaceutical products:
None